AlphaRose are a team of scientists, biotech professionals, and parents making medicines for children with rare genetic diseases.
Most of the 200 million children with a rare genetic disease will never see a treatment due to the current healthcare model. AlphaRose have discovered genetic technologies that can treat many of these diseases, and developed a business model that will bring treatments to many of these children.

AlphaRose acquired the Advent portfolio company Alpha Anomeric in 2025 and is now working to further develop and incorporate the Alpha Anomeric technology into new therapies.